In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Citius Oncology Inc (NASDAQ: CTOR) was $1.76 for the day, up 0.57% from the previous closing price of $1.75. In other words, the price has increased by $0.57 from its previous closing price. On the day, 0.59 million shares were traded. CTOR stock price reached its highest trading level at $1.94 during the session, while it also had its lowest trading level at $1.68.
Ratios:
Our analysis of CTOR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.02 and its Current Ratio is at 0.35. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Maxim Group on November 27, 2024, initiated with a Buy rating and assigned the stock a target price of $3.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTOR now has a Market Capitalization of 146983648 and an Enterprise Value of 141732224.
Stock Price History:
The Beta on a monthly basis for CTOR is 2.94, which has changed by -0.03296703 over the last 52 weeks, in comparison to a change of 0.1653893 over the same period for the S&P500. Over the past 52 weeks, CTOR has reached a high of $6.19, while it has fallen to a 52-week low of $0.55. The 50-Day Moving Average of the stock is -5.49%, while the 200-Day Moving Average is calculated to be 23.08%.
Shares Statistics:
CTOR traded an average of 1.72M shares per day over the past three months and 201950 shares per day over the past ten days. A total of 71.55M shares are outstanding, with a floating share count of 11.00M. Insiders hold about 86.83% of the company’s shares, while institutions hold 0.27% stake in the company. Shares short for CTOR as of 1756425600 were 303360 with a Short Ratio of 0.18, compared to 1753920000 on 299054. Therefore, it implies a Short% of Shares Outstanding of 303360 and a Short% of Float of 2.4600001.
Earnings Estimates
The market rating for Citius Oncology Inc (CTOR) is a result of the insights provided by 1.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.06, with high estimates of $0.06 and low estimates of $0.06.
Analysts are recommending an EPS of between -$0.48 and -$0.48 for the fiscal current year, implying an average EPS of -$0.48. EPS for the following year is $0.05, with 1.0 analysts recommending between $0.05 and $0.05.
Revenue Estimates
For the next quarter, 1 analysts are estimating revenue of $16.76M. There is a high estimate of $16.76M for the next quarter, whereas the lowest estimate is $16.76M.
Based on 1 analysts’ estimates, the company’s revenue will be $72.88M in the next fiscal year. The high estimate is $72.88M and the low estimate is $72.88M.
